Objectives: To determine whether the cytokine cardiotrophin-1 (CT-1) can protect the adult heart against ischaemia / reperfusion when added either prior to ischaemia or at reperfusion. Background: CT-1 has previously been shown to protect cultured embryonic or neonatal cardiocytes from cell death. To assess the therapeutic potential of CT-1, it is necessary to determine whether this effect can be observed in adult cardiac cells both in culture and most importantly in the intact heart. Methods: We examined the protective effect of CT-1 both in cultured adult rat cardiocytes and in the rat intact heart. In both cases, the cardiac cells were exposed to hypoxia / ischaemia followed by reoxygenation / reperfusion and CT-1 was administered either prior to hypoxia / ischaemia or at reoxygenation / reperfusion. Results: CT-1 has a protective effect in reducing ischaemic damage in the intact heart ex vivo as assayed by infarct size to area at risk ratio (20% compared to 35%). Similar protective effects against cell death were noted in adult cells in vitro. Both in vitro and ex vivo CT-1 can exert a protective effect when added at the time of reoxygenation / reperfusion as well as prior to the hypoxic / ischaemic stimulus (cell death reduced from 50 to 20% in TUNEL assay, infarct size to zone at risk ratio reduced from 35 to 20%). These protective effects are blocked by an inhibitor of the p42 / p44 MAPK pathway. Conclusion: CT-1 can protect adult cardiac cells both in vitro and in vivo when added both prior to or after the hypoxic / ischaemic stimulus. The potential therapeutic benefit of CT-1 when added at the time of reperfusion following ischaemic damage is discussed.
Introduction
which was capable of inducing cardiac myocyte hypertrophy in vitro [1] and was subsequently shown to have a Cardiotrophin-1 (CT-1) was initially isolated as a factor, similar effect when injected into adult mice [2] . Subsequent studies established that CT-1 is a member of a family of cytokines including interleukin-6 (IL-6), and IL-11 [3, 4] . The receptor for each of these factors Here we demonstrate that CT-1 has a protective effect in contains a common component known as gp130 (for both cultured adult cardiac cells and in the intact adult review see Refs. [5, 6] ). Although the IL-6, CNTF and heart ex vivo subjected to ischaemia / reperfusion. More-OSM receptors contain in addition a specific subunit which over, we demonstrate that both in vitro and ex vivo, CT-1 is unique to each of these receptors [5, 6] , LIF and CT-1 can have a protective effect when added at the time of and in certain cells, OSM share a common second receptor reperfusion / reoxygenation as well as when added prior to component, which is known as LIF receptor sub-unit b the ischaemic / hypoxic period and that these protective [3, 7] . Following binding to the receptor, members of the effects are blocked by an inhibitor of the p42 / p44 MAPK IL-6 family activate both the MAP kinase pathway and the pathway. Jak / STAT pathway resulting, respectively, in the phosphorylation of the transcription factors NF-IL6 and STAT-3 allowing them to stimulate transcription [5, [8] [9] [10] .
2. Methods As well as its potentially damaging hypertrophic effects, CT-1 also has significant protective effects. The apoptotic 2.1. Culture of adult cardiac cells death of unstressed embryonic or neonatal cardiac myocytes in defined serum-free medium can be reduced by Adult cardiac myocytes were isolated using a combinatreatment with CT-1 [11, 12] and this effect was inhibited tion of enzymatic and mechanical dispersion after Langenby inactivation of p42 / p44 MAP kinase, which had no dorff perfusion of the whole heart [20] [21] [22] . The hearts effect on the hypertrophic response to CT-1 [12] . This from adult female Sprague-Dawley rats, ranging in age effect, together with the expression of CT-1 in the early from 2 to 7 months, were excised and then rapidly mouse embryonic heart tube, suggests that CT-1 may have mounted on to the aortic cannula of a Langendorff significant effects on cardiac survival which are important perfusion system. The perfusion flow rate was kept conduring heart development [11] . Moreover, CT-1 may also stant at 9 ml / min per g of heart tissue. All buffers were play a key role in protecting cardiac cells against stressful heated to 37 8C and oxygenated with medically supplied stimuli. Thus, treatment of cultured neonatal cardiocytes oxygen (BOC gases). Initially, the heart was perfused for 2 with CT-1 protects them against subsequent exposure to min with modified Krebs-Hensliet (KH) buffer containing thermal or hypoxic stress both in terms of the total amount 21 of cell death observed and the extent of apoptosis [13] . However, in contrast to the hypertrophic effects of CT-1, glucose, pH 7.4, O -CO (95:5). The hearts were then 2 2 such protective effects have not yet been demonstrated in perfused with the above buffer containing 100 mM EGTA the intact heart, although a protective effect of CT-1 has for 4 min and finally with a Collagenase type 2 enzyme been demonstrated using atrial appendages derived from solution consisting of KH buffer supplemented with 0.8 adult human cardiac patients [14] . Indeed, CT-1 has never mg / ml Collagenase type 2 (Worthington Biochem) and 21 been tested for its protective effect in cultured adult as 200 mM Ca for 15 min. opposed to embryonic or neonatal cardiac cells. This is of
The left ventricle was removed from the heart and cut particular importance since CT-1 has been shown to induce into small pieces to increase the surface area for enzymatic the synthesis of protective heat shock proteins such as digestion in oxygenated ''shake solution'' [KH buffer hsp70 or hsp90 and other protective stimuli which induce supplemented with 0.8 mg / ml collagenase type 2, 10% 21 these proteins have been shown to be less effective in cells bovine serum albumin (BSA) (Sigma), 200 mM Ca ] for from aged compared to younger animals both in terms of 5 min in a 37 8C shaking water bath. The digested heart hsp induction and protective effect [15, 16] . Moreover, a tissue was passed through nylon gauze for filtration with wide variety of differences exist between cultured neonatal restore solution consisting of KH buffer supplemented with and adult cardiac cells [17, 18] [19] .
Laminin / ml in phosphate-buffered saline (PBS) for 2 h at room temperature in a laminar flow hood, prior to plating. minimal medium containing signal transduction inhibitors, For the annexin V labelling and TUNEL studies, cardiac prior to the 2-h incubation with 20 ng / ml of CT-1. myocytes were plated onto tissue culture slides (NUNC). The cells were pre-plated for 2 h and media was replaced 2.4. TUNEL labelling with fresh media for 24 h prior to experimentation. Cells were maintained in a 37 8C Heraeus incubator in a DNA degradation was assessed by the end labelling of humidified atmosphere under 5% CO in air. 2 DNA 39 ends with dUTP-FITC, using a modification of the TUNEL method [26] as previously described [27] [28] [29] tion of phosphatidyl serine to the outer surface of the HEPES, 20 mM sodium lactate, pH 6.2) for 6 h in an plasma membrane which occurs early in apoptosis [30] atmosphere of CO -argon (5:95) at 37 8C producing a 2 was carried out as previously described [27] [28] [29] . Only PO level of 4 mmHg [23] . CT-1 (Genentech) at a 2 cells staining positive for annexin V and negative for concentration of 20 ng / ml was added to the cardiac propidium iodide were scored as apoptotic to eliminate myocytes for 24 h and removed prior to a lethal hypoxic membrane permeable necrotic cells which take up both insult ( Fig. 1 ). For assays of the protective effect of CT-1 stains. added prior to hypoxia the cells were analysed immediately after the hypoxic period. The MEK1 inhibitor 2.6. Animals (PD98059) (New England Biolabs, Beverly, MA, USA) [24, 25] was stored at 220 8C at a concentration of 100
Male Sprague-Dawley rats (280-400 g body weight) mM and was added at a concentration of 50 mM, 10 min were used. All animals were obtained from the same prior to the addition of CT-1.
supplier, fed a standard pelleted diet with free access to water, housed under the same conditions and received 2.3. Reoxygenation humane care in accordance with the Guidelines on the Operation of the Animals (Scientific Procedures) Act For analysis of the protective effect of CT-1 added at the 1986, published by Her Majesty's Stationery Office (Lontime of reoxygenation, cardiac cell cultures were exposed don, UK). to 1 h of lethal hypoxia as described above and then incubated in a normoxic environment for 2 h (reoxygenation) ( Fig. 1) . At the point of reoxygenation the hypoxic 2.7. Heart perfusion and treatment protocol buffer was removed and replaced with 1 ml minimal media with and without the addition of 20 ng / ml of CT-1 for 2 h. The animals were anaesthetised by i.p. administration of To investigate the downstream signalling pathway which sodium pentobarbital (55 mg / kg) and were given heparin mediates CT-1 cardioprotection in reperfusion injury the (300 IU). The hearts were excised, placed in chilled buffer cardiac myocytes were incubated for 10 min in 1 ml of solution and within 1 min mounted on a constant pressure (80 mmHg) Langendorff perfusion apparatus. They were perfused retrogradely through the ascending aorta with a modified KH hydrogencarbonate buffer containing (in mM): NaCl 118.5, NaHCO 25, KCl 4.8, MgSO 1.2 3 4 KH PO 1.2, CaCl 1.7, glucose 12. All solutions were the help of water heated double jacket chambers. The temperature was permanently monitored by a thermocouple inserted in the right ventricle. The pH of the perfusate was ascertained with a blood gas analyser (AVL type 993; AVL Instruments, Stone, UK) and adjusted as necessary to maintain pH close to 7.4 (60.05) by modifying the gas output. A latex isovolumic balloon was introduced into the left ventricle through an insertion in the left atrial appendage and inflated to give a preload of 2-15 mmHg. The balloon catheter was attached by a pressure transducer to a Left ventricular developed pressure, heart rate and corfor details of the experimental protocol). Cell survival was onary flow were registered at regular intervals.
assayed by the trypan blue exclusion assay which measures A 4 / 0 silk suture on a round bodied surgical needle total cell death, both necrotic and apoptotic on the basis of (Mersilk type W546, Ethicon, Edinburgh, UK) was passed the ability of live cells to exclude trypan blue. under the left main coronary artery and the ends of the As illustrated in Fig. 2 , a dose of 20 ng / ml was able to suture were passed through a small plastic tube to form a produce a similar statistically significant protection against snare. Regional ischaemia was induced by tightening the hypoxia in cells from neonatal rats aged 2 days or adult snare and clamping in place with haemostat forceps. rats aged 2, 4 and 7 months. Interestingly, however, whilst Reperfusion was instituted by releasing the ends of the a significant protective effect could be observed in the suture.
neonatal cultures at a dose of CT-1 of 2 ng / ml in Six groups are included in the study (Fig. 6) . Group (i):
accordance with our earlier results [13] , this was not seen control, (n58) 20 min perfusion without intervention in the adult cultures. In other experiments, doses of 5 followed by 35 min coronary occlusion and 120 min ng / ml or 10 ng / ml of CT-1 were also ineffective in adult reperfusion; Group (ii): CT-1 pre-ischaemia, (n58) 30 min cultures whereas 30 ng / ml CT-1 had the same effect as 20 perfusion of 10 mg CT-1 / 1 of the buffer was followed by a ng / ml (data not shown). Hence, adult cultures can be 35 min period of ischaemia and 120 min reperfusion.
protected against subsequent exposure to hypoxia by CT-1 Group (iii): (n58) following 35 min ischaemia CT-1 (10 but a higher dose is required compared to that needed in mg / l) was perfused for 30 min at the beginning of 120 min cultures from younger neonatal animals. 20 ng / ml CT-1 reperfusion. Group (iv): (n58) following 35 min ischaemia was used in all subsequent experiments. PD (5 mM) and CT-1 (10 mg / l) was perfused together for As well as investigating the effect of CT-1 using the 30 min at the beginning of 120 min reperfusion. Group (v):
trypan blue exclusion assay we also utilised the TUNEL (n56) following ischaemia PD (5 mM) alone was perfused labelling and annexin V assays to measure the effect on cell for 30 min at the beginning of 120 min reperfusion. Group death using two additional methods in adult cultures. In (vi): (n58) CT-1 (10 mg / l) was perfused during the 35 these experiments (Fig. 3) , CT-1 treatment produced a min ischaemia. Infarct size was measured as previously clear protective effect in cultures of adult cells as assayed described [27] .
by the two different methods confirming the protective effect of CT-1 in cultured adult cardiac cells exposed to 2.8. Statistical analysis hypoxia.
The protective effect of CT-1 against cell death in Data for in vitro experiments are expressed as means6S.D. Single-factor analysis of variance (ANOVA) was performed for each group of treatments and significance was assumed when the P-value was less than 0.05. Differences among means were compared within the treatment groups using the Student's t-test. The experiments were repeated at least three times for each experiment, each n number corresponds to the mean of three random fields per well of cells with a minimum of 250 cells scored per view. Infarct size data were tested for group differences by one-way ANOVA combined with Tukey's posthoc test. ANOVA, P values and the Student's t-test values that were less than *,0.05, were considered significant.
Results
Previous animal work showing protective effects of CT-1 has been conducted in embryonic or neonatal cardiac cultures which are of limited relevance to any potential therapeutic situation [11] [12] [13] . We therefore wished to in cardiac cultures prepared from neonatal or adult rats of the indicated ages. Cell death was assayed by trypan blue exclusion immediately after evaluate the protective effect of CT-1 in cultures from exposure to simulated ischaemia. In each case, cell death in the CT-1 adult rats and compare it to that observed in neonatal treated cells was expressed as a percentage of the amount of death cultures. Accordingly, CT-1 was added at different doses observed in untreated cultures from each age animal exposed to hypoxia to cardiocyte cultures derived from rats of different ages (set at 100%). Values are the mean of three experiments whose standard and 24 h later the cells were exposed to hypoxia (see Fig. 1 deviation is shown by the bars. *5P,0.05. and cells analysed after two h reoxygenation (see Fig. 1 for experimental protocol). In these experiments we were able The protective effect of CT-1 when added prior to hypoxia and more particularly its protective effect when added immediately prior to reoxygenation in cultures of neonatal cardiocytes grown in serum-free medium or cardiac cells from adult rats suggested a potential therapeuexposed to hypoxia has previously been shown to be inhibited by PD98059, a specific inhibitor of the p42 / p44 MAP kinase pathway which acts by inhibiting the activity of the upstream activator of these kinases MEK1 [12, 29] . The protective effect of CT-1 against hypoxia was therefore investigated in our adult cultures using the trypan blue exclusion assay in the presence or absence of this inhibitor. In these experiments (Fig. 4) the PD98059 p42 / p44 MAPK inhibitor completely blocked the protective effect of CT-1 in cultures from 6-month-old animals. This suggests that, as with the protective effect in neonatal cultures, the protective effect of CT-1 involves the MEK1 kinase, which specifically activates the p42 / p44 MAP kinase pathway. No significant effect of PD98059 on cell survival was observed in the absence of CT-1 confirming that the effect of PD98059 specifically involved blocking the protective effect of CT-1. Similar inhibition of the protective effect of CT-1 by PD98059 was also observed in TUNEL and annexin V assays (data not shown). tic use for this factor in individuals suffering cardiac However, CT-1 had a clear protective effect when added ischaemic episodes. Despite this protective effect in vitro prior to the period of ischaemia, significantly reducing the however, no protective effect of CT-1 against cell death in degree of damage observed in the heart as measured by the the intact adult heart has, to our knowledge, been demonratio of infarct size to zone at risk ( Fig. 7 and Table 3 ). strated either prior to or after the ischaemic period. We
Most importantly however, a significant protective effect therefore investigated the protective effect of CT-1 in the was also observed when CT-1 was added immediately intact heart perfused ex vivo in a Langendorff perfusion prior to reperfusion and subsequent to the period of apparatus (see Fig. 6 for the experimental protocol used in ischaemia. Hence, CT-1 can protect against injury when these experiments). In these experiments, no alteration in added after the ischaemic period and unlike the great haemodynamic parameters such as left ventricular demajority of proposed protective agents (such as b-blockers, veloped pressure, heart rate and coronary flow rate was calcium antagonists and nitrates) can have an effect when observed in any of the groups either at baseline or added after, as well as before, the period of ischaemia. following ischaemia (Tables 1 and 2) . Similarly, the sizes Moreover, as observed in our in vitro experiments, the of the zone at risk were similar in all groups (Table 3) .
protective effect of CT-1 added at reperfusion was All data expressed as mean6S.E. There are no significant differences between groups. LVEDP5Left ventricular end diastolic pressure; RPP5rate pressure product (heart ratex developed pressure); CFR5coronary flow rate; CT-1 PreI5perfusion with CT-1 preischaemia for 30 min; CT-1 Rep5perfusion with CT-1 at the beginning of reperfusion for 30 min; PD&CT-15perfusion with PD and CT-1 at the beginning of reperfusion for 30 min; PD Rep5perfusion with PD at the beginning of reperfusion for 30 min; CT-1 Isch5perfusion with CT-1 during the 35 min of ischaemia. All data expressed as mean6S.E. There are no significant differences between groups. Ischaem-3595At 35 min of ischaemia; Reperf-3095at 30 min of reperfusion; Reperf-6095at 60 min of reperfusion; Reperf-9095at 90 min of reperfusion; Reperf-12095at 120 min of reperfusion; RPP5rate pressure product (heart ratex developed pressure); CFR5coronary flow rate; CT-1 PreI5perfusion with CT-1 preischaemia for 30 min; CT-1 Rep5perfusion with CT-1 at the beginning of reperfusion for 30 min; PD&CT-15perfusion with PD and CT-1 at the beginning of reperfusion for 30 min; PD Rep5perfusion with PD at the beginning of reperfusion for 30 min; CT-1 Isch5perfusion with CT-1 during the 35 min of ischaemia.
abolished by addition of PD98059 indicating it could be 4. Discussion prevented by an inhibitor of the p42 / p44 MAPK pathway. Interestingly CT-1 also produced a protective effect when
The development of methods for reducing the damage added during ischaemia. This effect is likely to be partly suffered by individuals undergoing episodes of cardiac dependent on the small amount (approximately 6%) of ischaemia is evidently of central importance in cardiology. collateral flow, which occurs in the rat [31] . However, it is Many studies in this area have been carried out with also likely to be due to this CT-1 entering the heart at cardiac cultures from neonatal animals since these are reperfusion on release of the occlusion and producing a easier to culture than those from adult animals. However, protective effect in this manner.
these neonatal cells are different from adult cells in their ability to divide in culture and are not fully differentiated in terms of morphology, biochemistry, etc. Most impor- tantly, they differ in terms of energy metabolism from neonatal cardiocytes the protective effect of CT-1 against adult cells and hence are likely to respond to ischaemia apoptosis is dependent upon its ability to activate p42 / p44 differently. It is necessary therefore to confirm any work MAP kinase and appears to be independent of its activacarried out in neonatal cardiocyte cultures by carrying out tion of the Jak / STAT pathway [12, 29] . In contrast, the similar experiments using adult cardiac cells.
hypertrophic effect of CT-1 was not inhibited by inhibition Here we show that the cytokine CT-1 has a protective of the p42 / p44 MAPK pathway [12] . In the work preeffect in cultured cardiac cells from adult animals as well sented here, we have similarly demonstrated that the as its previously demonstrated protective effect in cardiac protective effect of CT-1 in adult cardiac cells both in vitro cells from neonatal or embryonic animals [11] [12] [13] . These and in the intact heart ex vivo can be abolished by studies in rat ventricular myocytes are in agreement with a treatment with PD98059, a specific inhibitor of the p42 / recent study which showed a protective effect of CT-1 in p44 MAP kinase pathway. Hence these novel protective human atrial appendages taken from adult human cardiac effects are also likely to be dependent on this pathway. patients [14] . The protective effect of CT-1 in adult cells, IL-6 family cytokines are able to activate the NF-IL6 is of particular importance in view of the differences transcription factor by MAP kinase-dependent phosphorylbetween adult and neonatal cardiac cells and indeed we ation [8, 37] . Hence, newly activated NF-IL6 could activate observed that higher doses of CT-1 were required for the the transcription of genes encoding protective proteins protective effect in adult cultures. This requirement for a resulting in the protective effect of CT-1. Indeed, we have higher concentration of CT-1 may reflect a lower conpreviously demonstrated that in neonatal cardiocytes CT-1 centration of either the gp130 or LIF receptor b comcan enhance the expression of the protective heat shock ponents of the CT-1 receptor in adult cells or a lower proteins hsp70 and hsp90 whose transcription is known to sensitivity of intra-cellular signalling pathways to activabe stimulated by activated NF-IL6 [38] . We also observed tion by CT-1. Further studies will be necessary to investisuch induction in adult cells in our study (data not shown), gate these possibilities.
although it is still unclear whether the induction of these Most importantly, we observed a protective effect of proteins is essential for the protective effect of CT-1. CT-1 in the intact perfused heart exposed to ischaemia, the Further studies will be required in order to demonstrate first time such an effect has been demonstrated in this the protective effect of CT-1 in the intact adult animal as situation. Moreover, both in the cultured adult cells and in well as in the ex vivo heart preparation. Similarly, it will the intact adult heart CT-1 can be effective at minimising be important to identify the mechanisms by which CT-1 the damage caused by a period of ischaemia / hypoxia activation of the p42 / p44 MAP kinase pathway results in followed by reperfusion / re-oxygenation when given at the enhanced protection in adult cardiac cells. This is of time of reperfusion / re-oxygenation as well as prior to the particular importance since it may well lead to a method of ischaemic / hypoxic period. Hence, CT-1 is able to exert a activating this protective pathway either with CT-1 or protective effect against the damage, which occurs during related agents without activating the potentially damaging reperfusion / re-oxygenation following a period of ishypertrophy pathway which is also activated by CT-1, chaemia / hypoxia. hence allowing therapeutic advantage to be taken of the To date, no studies have demonstrated conclusively that ability of CT-1 to have a protective effect in the adult heart pharmacological agents given at the time of reperfusion when given at the time of reperfusion following an can protect the myocardium from reperfusion induced ischaemic episode. lethal injury. Although controversial, some studies have demonstrated however that an inhibition of leukocyte activation is useful at the time of reperfusion [32] . In
